JP2020528911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528911A5 JP2020528911A5 JP2020504146A JP2020504146A JP2020528911A5 JP 2020528911 A5 JP2020528911 A5 JP 2020528911A5 JP 2020504146 A JP2020504146 A JP 2020504146A JP 2020504146 A JP2020504146 A JP 2020504146A JP 2020528911 A5 JP2020528911 A5 JP 2020528911A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigenic
- reprna
- ivt
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 95
- 230000000890 antigenic effect Effects 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 230000037452 priming Effects 0.000 claims description 19
- 230000002163 immunogen Effects 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 241000701161 unidentified adenovirus Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 241000598171 Human adenovirus sp. Species 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538070P | 2017-07-28 | 2017-07-28 | |
| US62/538,070 | 2017-07-28 | ||
| US201762546259P | 2017-08-16 | 2017-08-16 | |
| US62/546,259 | 2017-08-16 | ||
| PCT/US2018/044075 WO2019023566A1 (en) | 2017-07-28 | 2018-07-27 | METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528911A JP2020528911A (ja) | 2020-10-01 |
| JP2020528911A5 true JP2020528911A5 (enExample) | 2021-08-26 |
| JP7311489B2 JP7311489B2 (ja) | 2023-07-19 |
Family
ID=63407511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504146A Active JP7311489B2 (ja) | 2017-07-28 | 2018-07-27 | 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11235051B2 (enExample) |
| EP (1) | EP3658179B1 (enExample) |
| JP (1) | JP7311489B2 (enExample) |
| KR (1) | KR102806640B1 (enExample) |
| CN (1) | CN111163799A (enExample) |
| AU (1) | AU2018306614B2 (enExample) |
| BR (1) | BR112020001052A2 (enExample) |
| CA (1) | CA3071011A1 (enExample) |
| IL (1) | IL272281B2 (enExample) |
| MA (1) | MA49693A (enExample) |
| SG (1) | SG11202000019RA (enExample) |
| WO (1) | WO2019023566A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113194988A (zh) * | 2018-12-14 | 2021-07-30 | 葛兰素史密斯克莱生物公司 | 异源初次免疫加强疫苗组合物及方法 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020146700A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Lipid nanoparticles |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| JP2023517644A (ja) * | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN116171150A (zh) | 2020-08-14 | 2023-05-26 | 阿克丘勒斯治疗公司 | 冻干脂质纳米颗粒的方法 |
| WO2022180007A1 (en) | 2021-02-23 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutation |
| CA3173950A1 (en) | 2021-03-22 | 2022-09-22 | Tyson D. BOWEN | Dna modifyng enzymes and active fragments and variants thereof and methods of use |
| CN115232824B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的预防狂犬病毒感染的疫苗 |
| EP4396359A4 (en) * | 2021-09-02 | 2025-09-17 | Replicate Bioscience Inc | ALPHAVIRUSES MODIFIED WITH HETEROLOGOUS NON-STRUCTURAL PROTEINS |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| CN116064597B (zh) * | 2023-01-17 | 2024-04-26 | 北京大学 | 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| DK1497440T3 (da) | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
| PT1497438E (pt) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
| US20050208020A1 (en) | 2003-11-12 | 2005-09-22 | Doolan Denise L | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| DK1711518T3 (da) | 2004-01-23 | 2010-04-06 | Angeletti P Ist Richerche Bio | Vaccinebærere for chimpanse-adenovirus |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| DK2146760T3 (en) | 2007-04-30 | 2019-01-28 | Medtronic Minimed Inc | FILLING OF RESERVOIR, BUBBLE MANAGEMENT AND DELIVERY SYSTEMS FOR INFUSION MEDIA AND PROCEDURES |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| PL3178490T3 (pl) * | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Kompozycje białka f rsv i sposoby ich wytwarzania |
| DK2590676T3 (en) | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| WO2012082918A1 (en) | 2010-12-14 | 2012-06-21 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| EP3632463A1 (en) * | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
| GB2513768B (en) * | 2012-07-06 | 2015-04-15 | Novartis Ag | Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins |
| US20140271714A1 (en) * | 2013-03-15 | 2014-09-18 | Monika Simmons | Induction of an immune response against dengue virus using the prime-boost approach |
| KR20190062617A (ko) | 2014-09-03 | 2019-06-05 | 버베리안 노딕 에이/에스 | 면역 반응을 증대시키기 위한 방법 및 조성물 |
| BE1023877B1 (fr) * | 2015-05-21 | 2017-09-01 | Glaxosmithkline Biologicals Sa | Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus |
-
2018
- 2018-07-27 AU AU2018306614A patent/AU2018306614B2/en active Active
- 2018-07-27 SG SG11202000019RA patent/SG11202000019RA/en unknown
- 2018-07-27 MA MA049693A patent/MA49693A/fr unknown
- 2018-07-27 KR KR1020207005743A patent/KR102806640B1/ko active Active
- 2018-07-27 CA CA3071011A patent/CA3071011A1/en active Pending
- 2018-07-27 IL IL272281A patent/IL272281B2/en unknown
- 2018-07-27 CN CN201880063070.8A patent/CN111163799A/zh active Pending
- 2018-07-27 US US16/634,205 patent/US11235051B2/en active Active
- 2018-07-27 EP EP18762177.6A patent/EP3658179B1/en active Active
- 2018-07-27 BR BR112020001052-9A patent/BR112020001052A2/pt unknown
- 2018-07-27 WO PCT/US2018/044075 patent/WO2019023566A1/en not_active Ceased
- 2018-07-27 JP JP2020504146A patent/JP7311489B2/ja active Active
-
2021
- 2021-12-22 US US17/645,556 patent/US11964007B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528911A5 (enExample) | ||
| Ewer et al. | A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA | |
| JP2014503206A5 (enExample) | ||
| Lázaro-Frías et al. | Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins | |
| JP7311489B2 (ja) | 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 | |
| JP2016539946A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| JP2019505560A5 (enExample) | ||
| JP2011500718A5 (enExample) | ||
| JP2019151636A5 (enExample) | ||
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2016506416A5 (enExample) | ||
| JP2017530124A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| JP2017513502A5 (enExample) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| JP2018536002A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| JP2002512026A5 (enExample) | ||
| JP2015506179A5 (enExample) | ||
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| JP2012021028A5 (enExample) | ||
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon |